CN Patent

CN112390788A — 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途

Assigned to Suzhou Wentian Pharmaceutical Technology Co ltd · Expires 2021-02-23 · 5y expired

What this patent protects

本发明公开了一种下式(I)表示的化合物及其异构体或药学上可接受的盐。所述化合物可以用于抑制KRASG12C突变蛋白和治疗相关的癌症。

USPTO Abstract

本发明公开了一种下式(I)表示的化合物及其异构体或药学上可接受的盐。所述化合物可以用于抑制KRASG12C突变蛋白和治疗相关的癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN112390788A
Jurisdiction
CN
Classification
—
Expires
2021-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Wentian Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.